| Literature DB >> 16670000 |
Matthew E Falagas1, Alexandra Bakossi, Vasilis D Pappas, Pierros V Holevas, Antonis Bouras, Eleni Stamata.
Abstract
BACKGROUND: Most of the studies evaluating the secular trends of blood isolates come from tertiary hospitals in urban areas. We sought to study the trends of the antimicrobial resistance of blood isolates in patients from a rural population hospitalized in a tertiary hospital in a small city in Greece.Entities:
Mesh:
Year: 2006 PMID: 16670000 PMCID: PMC1459861 DOI: 10.1186/1471-2180-6-41
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Number of admissions and total and positive blood cultures during each study period in General Hospital of Tripolis, Greece (16/05/2000–15/05/2005).
| Hospitalized patients | 12,625 | 12,655 | 13,559 | 13,835 | 14,396 | 67,070 | < 0.001 |
| Number of blood cultures obtained | 406 | 483 | 650 | 763 | 904 | 3,206 | < 0.001 |
| Ratio of admissions to blood cultures obtained | 31:1 | 26:1 | 21:1 | 18:1 | 16:1 | 21:1 | |
| Positive blood cultures (proportion from blood cultures obtained) | 46 (11.3) | 48 (9.9) | 71 (10.9) | 88 (11.5) | 120 (13.3) | 373 (11.6) | 0.39 |
Relative frequency of blood isolates in General Hospital of Tripolis, Greece (2001–2005).
| 15 (32.6) | 15 (31.3) | 26 (36.6) | 26 (29.5) | 52 (43.3) | 134 (35.9) | 0.28 | |
| 6 (13) | 9 (18.8) | 14 (19.7) | 21 (23.9) | 18 (15) | 68 (18.2) | 0.45 | |
| 1 (1.4) | 1 (0.3) | ||||||
| 20 (43.5) | 17 (35.4) | 22 (31) | 22 (25) | 27 (22.5) | 108 (29) | 0.06 | |
| 2 (4.3) | 3 (6.3) | 4 (5.6) | 11 (12.5) | 9 (7.5) | 29 (7.8) | ||
| 3 (4.2) | 2 (2.3) | 1 (0.8) | 6 (1.6) | ||||
| 1 (2.2) | 3 (6.3) | 0(0) | 0(0) | 2 (1.6) | 6 (1.6) | ||
| 1 (2.2) | 1 (2.1) | 0(0) | 0(0) | 2 (1.6) | 4 (1.1) | ||
| 1 (1.4) | 1 (0.3) | ||||||
| 1 (2.2) | 4 (4.6) | 7 (5.8) | 12 (3.2) | ||||
| 1 (0.8) | 1 (0.3) | ||||||
| 1 (1.1) | 1 (0.3) | ||||||
| 1 (1.1) | 1 (0.3) | ||||||
| 1 (0.8) | 1 (0.3) | ||||||
| 46 (100) | 48 (100) | 71 (100) | 88 (100) | 120 (100) | 373 (100) | ||
* for the isolate of the first positive blood culture
Trends of antimicrobial resistance of Gram-positive and Gram-negative bacteria in General Hospital of Tripolis, Greece (2001–2005).
| Oxacillin* | 0/15 (0) | 6/15 (40) | 7/26 (26.9) | 13/56 (23.2) | ||
| Gentamicin | 2/15 (13.3) | 1/15 (6.7) | 1/26 (3.8) | 0/26 (0) | 9/52 (17.3) | 13/134 (9.7) |
| Vancomycin | 0/15 (0) | 0/15 (0) | 0/26(0) | 0/26 (0) | 0/52 (0) | 0/134 (0) |
| Penicillin | 13/26 (50) | 40/52 (76.9) | 53/78 (67.9) | |||
| Oxacillin* | 0/6 (0) | 5/9 (55.6) | 0/14 (0) | 5/29 (17.2) | ||
| Gentamicin | 1/6 (16.7) | 1/9 (11.1) | 0/14 (0) | 3/21 (14.3) | 1/18 (5.6) | 6/68 (8.8) |
| Vancomycin | 0/6 (0) | 0/9 (0) | 0/14 (0) | 0/21 (0) | 0/18 (0) | 0/68 (0) |
| Penicillin | 14/21 (66.7) | 13/18 (72.2) | 27/39 (69) | |||
| Penicillin | 0/1 (0) | 0/1 (0) | ||||
| Vancomycin | 0/1 (0) | 0/1 (0) | ||||
| Trimethoprim-sulfamethoxazole | 8/20 (40) | 6/17 (35.2) | 6/22 (27.2) | 6/22 (27.2) | 6/27 (22.2) | 32/108 (29.6) |
| Amikacin | 8/20 (40) | 4/17 (23.5) | 1/22 (4.5) | 0/22 (0) | 6/27 (22.2) | 19/108 (17.6) |
| Gentamicin | 2/20 (10) | 4/17 (23.5) | 0/22 (0) | 0/22 (0) | 2/27 (7.4) | 8/108 (7.4) |
| Ampicillin | 3/20 (15) | 0/17 (0) | 6/22 (27.2) | 8/22 (36.3) | 10/27 (37.0) | 27/108 (25.0) |
| Cefuroxime | 0/20 (0) | 0/17 (0) | 2/22 (9.1) | 1/22 (4.5) | 6/27 (22.2) | 9/108 (8.3) |
| Amikacin | 0/2 (0) | 0/3 (0) | 0/4 (0) | 0/11 (0) | 3/9 (33.3) | 3/29 (10.3) |
| Ceftazidime | 0/2 (0) | 0/3 (0) | 0/4 (0) | 2/11 (18.2) | 2/9 (22.2) | 4/29 (13.8) |
| Ciprofloxacin | 1/2 (50) | 0/3 (0) | 0/4 (0) | 4/11 (36.4) | 3/9 (33.3) | 8/29 (27.6) |
| Imipenem | 0/2 (0) | 0/3 (0) | 0/4 (0) | 0/11 (0) | 1/9 (11.1) | 1/29 (3.4) |
| Amikacin | 0/3 (0) | 1/2 (50) | 0/1 (0) | 1/6 (16.7) | ||
| Gentamicin | 0/3 (0) | 0/2 (0) | 0/1 (0) | 0/6 (0) | ||
| Ceftazidime | 3/3 (100) | 1/2 (50) | 0/1 (0) | 4/6 (66.7) | ||
| Ciprofloxacin | 3/3 (100) | 2/2 (100) | 0/1 (0) | 5/6 (83.3) | ||
| Imipenem | 0/3 (0) | 0/2 (0) | 1/1 (100) | 0/6 (0) | ||
| Ceftazidime | 0/1 (0) | 0/2 (0) | 0/3 (0) | |||
| Ciprofloxacin | 0/1 (0) | 1/2 (50) | 1/3 (33.3) | |||
| Meropenem | 0/1 (0) | 0/2 (0) | 0/3 (0) | |||
| Cefepime | 0/1 (0) | 0/2 (0) | 0/3 (0) | |||
| Cefoxitin | 1/1 (100) | 0/2 (0) | 1/3 (33.3) | |||
| Tobramycin | 0/1 (0) | 0/2 (0) | 0/3 (0) | |||
* Oxacillin discs were not available for antimicrobial testing during the period 16/05/2003 – 15/05/2005